Trulieve Cannabis (TCNNF) Receives a Buy from Needham

According to, McGinley is a 5-star analyst with an average return of 76.3% and a 69.1% success rate. McGinley covers the Basic Materials sector, focusing on stocks such as Green Thumb Industries, Curaleaf Holdings, and Aurora Cannabis.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trulieve Cannabis with a $68.91 average price target, a 72.3% upside from current levels. In a report issued on April 30, Cantor Fitzgerald also maintained a Buy rating on the stock with a $89.00 price target.

See today’s analyst top recommended stocks >>

Trulieve Cannabis’ market cap is currently $4.73B and has a P/E ratio of 75.10. The company has a Price to Book ratio of 15.81.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.